诺西那生钠治疗脊柱侧凸脊髓性肌萎缩症患者的疗效及安全性研究

doi:10.12372/jcp.2025.24e1128

临床儿科杂志 ›› 2025, Vol. 43 ›› Issue (10): 727-733.doi: 10.12372/jcp.2025.24e1128

诺西那生钠治疗脊柱侧凸脊髓性肌萎缩症患者的疗效及安全性研究

刘昕竹¹, 幸小东¹, 刘宇², 刘艳¹, 蒋文高³, 张健¹(), 杨军林²()

1.临床药学部上海交通大学医学院附属新华医院（上海 200092）
2.脊柱中心上海交通大学医学院附属新华医院（上海 200092）
3.重庆医科大学药学院（重庆 400016）

收稿日期:2024-10-23 录用日期:2025-07-09 出版日期:2025-10-15 发布日期:2025-09-29
通讯作者: 张健,杨军林 E-mail:zhangjian@xinhuamed.com.cn;yangjunlin@xinhuamed.com.cn
基金资助:
上海交通大学医学院高水平地方高校建设项目;教育部·上海市临床与转化医学协同创新中心重点科研项目(CCTS-2022205)

Efficacy and safety of nusinersen in spinal muscular atrophy patients with scoliosis

LIU Xinzhu¹, XING Xiaodong¹, LIU Yu², LIU Yan¹, JIANG Wengao³, ZHANG Jian¹(), YANG Junlin²()

1. Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
2. Spine Center, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
3. College of Pharmacy, Chongqing Medical University, Chongqing 400016, China

Received:2024-10-23 Accepted:2025-07-09 Published:2025-10-15 Online:2025-09-29
Contact: ZHANG Jian, YANG Junlin E-mail:zhangjian@xinhuamed.com.cn;yangjunlin@xinhuamed.com.cn

摘要/Abstract

摘要：

目的探究诺西那生钠在合并脊柱侧凸脊髓性肌萎缩症（spinal muscular atrophy，SMA）患者中的疗效及安全性。方法回顾性分析2022年1月至2024年6月脊柱中心规律接受诺西那生钠治疗的脊柱侧凸SMA患者的临床资料，包括电子病历系统采集的基本信息、手术史、影像学检查等。随访期间，选用患者上肢模块修订版评分（RULM）、汉默史密斯功能性运动量表扩展版（HFMSE）和脊髓性肌萎缩症独立量表-上肢模块（SMAIS-ULM）三种量表对患者进行评估，并与治疗前基线数据比较。结果共22例SMA患者被纳入分析，中位年龄13.2(9.8~21.8)岁，近半数患者（41%）独坐不能，治疗前Cobb角101.0(42.3~121.3)度，其中17例患者（77.3%）在随访期内接受了脊柱侧凸矫正手术，中位随访时间22(13~26)月。经诺西那生钠治疗后，患者RULM评分提升（P<0.001），18例患者（81.8%）的运动功能得到具临床意义的改善。此外，患者及照护者的SMAIS-ULM评分也有提升。治疗过程中，13例患者（59.1%）报告了头晕、恶心、鞘注部位疼痛等不良反应，另有2例出现腹泻、脱发。结论诺西那生钠能改善合并脊柱侧凸SMA患者的上肢运动功能并提高其生活自理独立性，该效果独立于手术影响，且安全性良好。

关键词: 脊髓性肌萎缩症, 诺西那生钠, 脊柱侧凸

Abstract:

Objective To investigate the efficacy and safety of nusinersen in patients with spinal muscular atrophy (SMA) complicated by scoliosis. Methods A retrospective analysis was performed on the clinical data of SMA patients with scoliosis who regularly received nusinersen treatment at the Spinal Center of our hospital from January 2022 to June 2024. The data encompassed basic information, surgical history, imaging examinations, etc., collected from the electronic medical record system. During the follow-up period, three scales, namely the Revised Upper Limb Module (RULM) score, the Hammersmith Functional Motor Scale-Expanded (HFMSE), and the Spinal Muscular Atrophy Independence Measure-Upper Limb Module (SMAIS-ULM), were employed to assess the patients. The results of these assessments were compared with pre-treatment baseline data. Results A total of 22 SMA patients were included in the analysis. The median age was 13.2 (9.8-21.8) years, and nearly half of the patients (41%) were unable to sit independently. The median pre-treatment Cobb angle was 101.0 (42.3-121.3) degrees, and 17 of these patients (77.3%) underwent scoliosis correction surgery during follow-up period. The median follow-up duration was 22 (13-26) months. After treatment with nusinersen, the RULM scores of the patients were significantly improved (P<0.001). The motor function of 18 patients (81.8%) showed clinically meaningful improvement. Moreover, the SMAIS-ULM scores of both the patients and their caregivers also increased. During the treatment process, 13 patients (59.1%) reported adverse reactions such as dizziness, nausea, and pain at the site of intrathecal injection. Additionally, 2 patients presented with diarrhea and alopecia. Conclusions Nusinersen has been shown to improve upper limb motor function in SMA patients complicated by scoliosis and enhance their independence in daily activities. This effect appears to be independent of surgical intervention and is associated with a favorable safety profile.

Key words: spinal muscular atrophy, nusinersen, scoliosis

中图分类号:

刘昕竹, 幸小东, 刘宇, 刘艳, 蒋文高, 张健, 杨军林. 诺西那生钠治疗脊柱侧凸脊髓性肌萎缩症患者的疗效及安全性研究[J]. 临床儿科杂志, 2025, 43(10): 727-733.

LIU Xinzhu, XING Xiaodong, LIU Yu, LIU Yan, JIANG Wengao, ZHANG Jian, YANG Junlin. Efficacy and safety of nusinersen in spinal muscular atrophy patients with scoliosis[J]. Journal of Clinical Pediatrics, 2025, 43(10): 727-733.

图/表 3

表1

图1

图2

参考文献 26

[1]	Mercuri E, Sumner CJ, Muntoni F, et al. Spinal muscular atrophy[J]. Nat Rev Dis Primers, 2022, 8(1): 52. doi: 10.1038/s41572-022-00380-8 pmid: 35927425
[2]	Xing X, Liu X, Li X, et al. Insights into spinal muscular atrophy from molecular biomarkers[J]. Neural Regen Res, 2025, 20(7): 1849-1863.
[3]	杨军林, 隋文渊, 张天元. 脊髓性肌萎缩症合并脊柱侧凸的临床诊治[J]. 临床儿科杂志, 2022, 40(3): 161-164.
	Yang JL, Sui WY, Zhang TY. Clinical diagnosis and treatment of spinal muscular atrophy with scoliosis[J]. Linchuang Erke Zazhi, 2022, 40(3): 161-164.
[4]	Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care[J]. Neuromuscul Disord, 2018, 28(2): 103-115.
[5]	Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study[J]. Lancet, 2016, 388(10063): 3017-3026. doi: S0140-6736(16)31408-8 pmid: 27939059
[6]	李海冰, 夏雨, 叶文松, 等. 脊髓性肌萎缩症髋关节和脊柱畸形的初步研究[J]. 中华小儿外科杂志, 2020, 41(10): 926-932.
	Li MB, Xia Y, Ye WS, et al. Preliminary research of hipor spinal deformity in children with spinal muscular atrophy[J]. Zhonghua Xiaoer Waike Zazhi, 2020, 41(10): 926-932.
[7]	Glanzman AM, O'Hagen JM, McDermott MP, et al. Validation of the expanded Hammersmith functional notor scale in spinal muscular atrophy type II and III[J]. J Child Neurol, 2011, 26(12): 1499-1507. doi: 10.1177/0883073811420294 pmid: 21940700
[8]	Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module[J]. Muscle Nerve, 2017, 55(6): 869-874. doi: 10.1002/mus.25430 pmid: 27701745
[9]	Trundell D, Skalicky A, Staunton H, et al. Development of the SMA independence scale-upper limb module (SMAIS-ULM): a novel scale for individuals with Type 2 and non-ambulant Type 3 SMA[J]. J Neurol Sci, 2022, 432: 120059.
[10]	Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)[J]. Pediatr Phys Ther, 2011, 23(4): 322-326. doi: 10.1097/PEP.0b013e3182351f04 pmid: 22090068
[11]	Łusakowska A, Wójcik A, Frączek A, et al. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience[J]. Orphanet J Rare Dis, 2023, 18(1): 230. doi: 10.1186/s13023-023-02769-4 pmid: 37542300
[12]	Vázquez-Costa JF, Povedano M, Nascimiento-Osorio AE, et al. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy[J]. Eur J Neurol, 2022, 29(12): 3666-3675. doi: 10.1111/ene.15542 pmid: 36047967
[13]	Vázquez-Costa JF, Branas-Pampillón M, Medina-Cantillo J, et al. Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study[J]. Neurol Ther, 2023, 12(1): 89-105.
[14]	Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial[J]. Lancet Neurol, 2022, 21(1): 42-52. doi: 10.1016/S1474-4422(21)00367-7 pmid: 34942136
[15]	Chiriboga CA, Bruno C, Duong T, et al. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam[J]. J Neurol, 2024, 271(8): 4871-4884. doi: 10.1007/s00415-024-12318-z pmid: 38733387
[16]	Alves CRR, Petrillo M, Spellman R, et al. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series[J]. Mol Ther Methods Clin Dev, 2021, 23: 524-538.
[17]	Parnetti L, Gaetani L, Di Filippo M. Serum neurofilament light chain as a preclinical marker of neurodegeneration[J]. Lancet Neurol, 2019, 18(12): 1070-1071. doi: S1474-4422(19)30405-3 pmid: 31701888
[18]	Finkel RS, Ryan MM, Pascual Pascual SI, et al. Scientific rationale for a higher dose of nusinersen[J]. Ann Clin Transl Neurol, 2022, 9(6): 819-829.
[19]	Reilly A, Chehade L, Kothary R. Curing SMA: Are we there yet?[J]. Gene Ther, 2023, 30(1-2): 8-17.
[20]	Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges[J]. Nat Rev Neurol, 2018, 14(4): 214-224. doi: 10.1038/nrneurol.2018.4 pmid: 29422644
[21]	Lapp HS, Freigang M, Hagenacker T, et al. Biomarkers in 5q-associated spinal muscular atrophy-a narrative review[J]. J Neurol, 2023, 270(9): 4157-4178. doi: 10.1007/s00415-023-11787-y pmid: 37289324
[22]	Messina S, Pane M, Sansone V, et al. Expanded access program with nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience[J]. Neuromuscul Disord, 2017, 27(12): 1084-1086.
[23]	Labianca L, Weinstein SL. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion[J]. J Pediatr Orthop B, 2019, 28(4): 393-396. doi: 10.1097/BPB.0000000000000632 pmid: 30932967
[24]	Machida S, Miyagi M, Saito W, et al. Posterior spinal correction and fusion durgery in patients with spinal muscular atrophy-associated scoliosis for whom treatment with nusinersen was planned[J]. Spine Surg Relat Res, 2021, 5(2): 109-113. doi: 10.22603/ssrr.2020-0091 pmid: 33842719
[25]	Wang Z, Feng E, Jiao Y, et al. Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study[J]. Orphanet J Rare Dis, 2023, 18(1): 369. doi: 10.1186/s13023-023-02972-3 pmid: 38031122
[26]	Carson VJ, Young M, Brigatti KW, et al. Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy[J]. Muscle Nerve, 2022, 65(1): 51-59.

项目	合计(n=22)	Ⅰ型(n=4)	Ⅱ型(n=12)	Ⅲ型(n=6)
性别[n(%)]
男	8(36.4)	2(50.0)	3(25.0)	3(50.0)
女	14(63.6)	2(50.0)	9(75.0)	3(50.0)
发病年龄[M(P₂₅~P₇₅)]/岁	0.9(0.5~1.5)	0.4(0.3~0.5)	0.8(0.6~1.2)	1.5(1.4~6.3)
入组年龄[M(P₂₅~P₇₅)]/岁	13.2(9.8~21.8)	4.8(0.6~18.0)	12.6(9.8~18.3)	19.1(13.6~26.1)
体质指数[M(P₂₅~P₇₅)/ kg·m^-2]	16.8(12.9~22.5)	13.3(9.4~16.1)	16.8(13.1~22.7)	18.9(15.9~24.1)
独走[n(%)]	2(9.0)	1(50.0)	1(50.0)	0(0)
独坐[n(%)]	11(50.0)	1(9.1)	6(54.5)	4(36.4)
SMN2的拷贝数[n(%)]
2拷贝	3(13.6)	1(33.3)	0(0)	2(66.7)
3拷贝	18(81.8)	3(16.7)	12(66.7)	3(16.7)
4拷贝	1(4.5)	0(0)	0(0)	1(100)
Cobb角[M(P₂₅~P₇₅)]/°	101.0(42.3~121.3)	59.0(12.3~120.0)	100.0(48.5~117.5)	105.5(75.0~142.8)
脊柱侧凸矫正术[n(%)]	17(77.3)	2(11.8)	10(58.8)	5(29.4)
肺通气功能限制性障碍[n(%)]	8(36.4)	2(25.0)	4(50.0)	2(25.0)
吞咽困难、饮水呛咳[n(%)]	6(27.3)	2(33.3)	3(50.0)	1(16.7)

诺西那生钠治疗脊柱侧凸脊髓性肌萎缩症患者的疗效及安全性研究

Efficacy and safety of nusinersen in spinal muscular atrophy patients with scoliosis

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 26

相关文章 11

Metrics

本文评价

推荐阅读 0

[1]	. 儿童脊髓性肌萎缩症症状前治疗专家共识（2025版）[J]. 临床儿科杂志, 2025, 43(9): 643-651.
[2]	段浩林, 张慈柳, 熊娟, 庞楠, 尹飞, 彭镜. SMN1基因复合杂合变异脊髓性肌萎缩症患者疾病修正治疗的临床疗效分析[J]. 临床儿科杂志, 2025, 43(7): 543-548.
[3]	王帆, 马飞, 戴文静, 肖冰, 潘晨麟. 脊髓性肌萎缩症多学科诊疗应用进展[J]. 临床儿科杂志, 2025, 43(3): 233-236.
[4]	幸小东, 刘艳, 刘昕竹, 蒋文高, 张健. 脊髓性肌萎缩症患者脊柱矫形围手术期治疗药物管理[J]. 临床儿科杂志, 2025, 43(1): 70-76.
[5]	吴献, 刘艳, 刘昕竹, 黄晓会, 马婧, 徐阿晶, 幸小东, 蒋文高, 张健. 脊髓性肌萎缩症疾病修正治疗真实世界研究进展[J]. 临床儿科杂志, 2025, 43(1): 61-69.
[6]	何冠兰, 韦秋芬, 李娜, 陈少萍, 刘云媛, 廖莎莎, 唐秀能. 诺西那生钠治疗脊髓性肌萎缩症患儿临床疗效的meta分析[J]. 临床儿科杂志, 2023, 41(12): 946-954.
[7]	罗智强, 路新国, 刘丽琴, 廖建湘. 诺西那生钠治疗症状前5q脊髓性肌萎缩症1例疗效分析[J]. 临床儿科杂志, 2022, 40(3): 208-211.
[8]	毛姗姗. 精准医学时代中国脊髓性肌萎缩症诊治发展之路[J]. 临床儿科杂志, 2022, 40(3): 165-169.
[9]	杨军林, 隋文渊, 张天元. 脊髓性肌萎缩症合并脊柱侧凸的临床诊治[J]. 临床儿科杂志, 2022, 40(3): 161-164.
[10]	周露露, 丁乐, 郑帼. TBCD基因变异致微管蛋白病伴非典型脊髓性肌萎缩症1例报告[J]. 临床儿科杂志, 2022, 40(11): 854-857.
[11]	张蕾,　颉小玲,　李娟,　柴晓静,　朱俊芳. 脊髓性肌萎缩症遗传学及治疗研究进展[J]. 临床儿科杂志, 2017, 35(8): 632-.